Fibrodysplasia Ossificans Progressiva Pipeline Research 2023: Focus on 5+ Companies and 7+ Pipeline Drugs - Analysis of the Advancements and Potential Breakthroughs
15 Jul 2023
Orphan DrugFast TrackPhase 2Phase 3
DUBLIN, July 14, 2023 /PRNewswire/ -- The "Fibrodysplasia Ossificans Progressiva - Pipeline Insight, 2023" clinical trials has been added to
ResearchAndMarkets.com's offering.
With a focus on 5+ companies and 7+ pipeline drugs, this report provides a detailed analysis of the advancements and potential breakthroughs in Fibrodysplasia ossificans progressiva treatment.
The report dives into pipeline drug profiles, encompassing both clinical and nonclinical stage products. It also includes a thorough assessment of therapeutics based on product type, stage, route of administration, and molecule type. In addition, the report sheds light on the inactive pipeline products within this space, providing a comprehensive overview of the Fibrodysplasia ossificans progressiva pipeline landscape.
Within the field of Fibrodysplasia ossificans progressiva research and development, companies and academics are diligently working to assess challenges and seek opportunities. The therapies currently under development focus on novel approaches to treat and improve Fibrodysplasia ossificans progressiva. This report unveils these innovative therapies and offers insights into the potential future of Fibrodysplasia ossificans progressiva treatment.
Stay informed and gain a competitive edge with this comprehensive guide to the latest advancements and pipeline drugs in the field of Fibrodysplasia ossificans progressiva treatment.
Fibrodysplasia ossificans progressiva Emerging Drugs Chapters
This segment of the Fibrodysplasia ossificans progressiva report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibrodysplasia ossificans progressiva Emerging Drugs
REGN2477: Regeneron Pharmaceuticals
REGN2477 (also known as garetosmab) is an antibody that binds to Activin A and blocks its activity. By binding and blocking Activin A, REN2477 prevents the formation and growth of HO in FOP. REGN2477 has received Orphan Drug status for FOP from the US Food and Drug Administration (FDA), and orphan status for the treatment of FOP in the EU. Currently, the drug is being evaluated in the Phase III clinical trial for the treatment of Fibrodysplasia ossificans progressiva.
IPN60130: Ipsen
IPN60130 (Fidrisertib) is an oral investigational drug designed to selectively target the mutant FOP receptor (ACVR1/ALK2), the underlying cause of FOP. FDA has granted Fast Track Designation to IPN60130 for the treatment of FOP. Currently, the drug is being evaluated in the Phase II clinical trial for the treatment of Fibrodysplasia ossificans progressiva.
Fibrodysplasia ossificans progressiva: Therapeutic Assessment
This segment of the report provides insights about the different Fibrodysplasia ossificans progressiva drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Fibrodysplasia ossificans progressiva
There are approx. 5+ key companies which are developing the therapies for Fibrodysplasia ossificans progressiva. The companies which have their Fibrodysplasia ossificans progressiva drug candidates in the most advanced stage, i.e. phase III include, Regeneron Pharmaceuticals.
Phases
The report covers around 7+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Fibrodysplasia ossificans progressiva Report Insights
Fibrodysplasia ossificans progressiva Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Fibrodysplasia ossificans progressiva Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Players
Ipsen
Daiichi Sankyo
Key Products
REGN2477
INCB000928
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/qwuemh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.